Development

Articles

FDA has approved Novo Nordisk’s Rybelsus (semaglutide), a glucagon-like peptide receptor protein treatment in oral tablet form for type 2 diabetes.

FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes

The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.

Nanoform Invests in Nanoparticle Technology for Drug Development

Sensors and devices being developed by nGageIT Digital Health Solutions can track patient use of oral solid-dosage or injectable drugs. 

Sensor Technology Aims to Improve Medication Adherence

Adeline Siew is science editor for BioPharm International.

There is a lot of interest in delivering biologics via non-invasive routes in attempt to improve patient compliance and convenience. 


Formulation of Biologics for Non-Invasive Delivery

Randi Hernandez was science editor at BioPharm International from September 2014 to May 2017.

A new study examines the oral delivery of protein drugs in plant cells and hypothesizes that the cold storage and transportation of biologics could someday be eliminated.

Are Oral Peptide Drugs on the Horizon?

The company announced plans to begin PIONEER, a Phase IIIa program comprising seven trials of approximately 8000 people with type 2 diabetes.

Novo Nordisk to Start Phase IIIa Trials for Oral Biologic

FDA issues draft guidance on dissolution testing for immediate-release solid oral dosage forms.

FDA Issues Dissolution Testing Guidance

Almac's Clinical Services business unit has expanded its service offering for dispensing and bottling solid dosage products.

Formulation and Drug Delivery, Solid Dosage